SCHEMBL840177

SCHEMBL840177

Cn1c(C(=O)Nc2ccc3c(c2)nc2n3CCC2)cc2cc(F)ccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.49
THRB P10828 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
LMNA P02545 4/20 0.46
RXFP1 Q9HBX9 1/20 0.46
RAB9A P51151 6/20 0.46
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HPGD P15428 1/20 0.46
TP53 P04637 6/20 0.45
NPC1 O15118 5/20 0.45
MAPK1 P28482 2/20 0.44
MAPT P10636 4/20 0.44
USP2 O75604 2/20 0.44
POLB P06746 1/20 0.44
GFER P55789 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL840563 0.88 TP53 (0.49) APPTHRBSMN1; SMN2LMNARAB9A
SCHEMBL833715 0.82 RAB9A (0.47) APPSMN1; SMN2LMNARAB9AALDH1A1
SCHEMBL832828 0.82 APP (0.44) APPSMN1; SMN2PTGDR2LMNARAB9A
SCHEMBL832026 0.81 TP53 (0.44) APPSMN1; SMN2LMNARAB9AALDH1A1
SCHEMBL832668 0.80 MAPT (0.41) APPSMN1; SMN2PTGDR2LMNARXFP1
SCHEMBL829962 0.80 RAB9A (0.50) APPSMN1; SMN2LMNARAB9AALDH1A1
SCHEMBL831540 0.80 LMNA (0.45) APPSMN1; SMN2LMNARAB9AALDH1A1
SCHEMBL832122 0.77 MEN1 (0.41) APPSMN1; SMN2PTGDR2LMNARXFP1
SCHEMBL832123 0.76 ALDH1A1 (0.42) APPSMN1; SMN2LMNARXFP1RAB9A
SCHEMBL14800259 0.76 MAPT (0.53) SMN1; SMN2LMNARAB9AALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143248-B2 Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use SANOFI-AVENTIS (FR) 2012-03-27 US disclosed
US-20090042873-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE SANOFI-AVENTIS (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042873-A1 TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE CYP3A5, CYP2C8, PAICS APP 3812/4885THRB 2878/4885SMN1; SMN2 3750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.